Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial Academic Article uri icon

abstract

  • We performed a subgroup analysis of the phase III UK National Cancer Research Institute R-CHOP-14 versus R-CHOP-21 (two- versus three-weekly rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) trial to evaluate the outcomes for 50 patients with World Health Organization 2008 classified primary mediastinal B-cell lymphoma identified from the trial database. At a median follow-up of 7·2 years the 5-year progression-free survival and overall survival was 79·8% and 83·8%, respectively. An exploratory analysis raised the possibility of a better outcome in those who received R-CHOP-14 and time intensification may still, in the rituximab era, merit testing in a randomised trial in this subgroup of patients.

authors

  • Gleeson, Mary
  • Hawkes, Eliza A
  • Cunningham, David
  • Chadwick, Nick
  • Counsell, Nicholas
  • Lawrie, Anthony
  • Jack, Andrew
  • Smith, Paul
  • Mouncey, Paul
  • Pocock, Christopher
  • Ardeshna, Kirit M
  • Radford, John
  • McMillan, Andrew
  • Davies, John
  • Turner, Deborah
  • Kruger, Anton
  • Johnson, Peter WM
  • Gambell, Joanna
  • Linch, David

publication date

  • 2016

has subject area